Tannin Specific Natural Extract for COVID-19 Infection
关键词
抽象
描述
The epidemic of 2019 novel coronavirus (causing the disease Covid-19) has expanded from Wuhan throughout China and is being exported to a growing number of countries, some of which have seen onward transmission. COVID-19 caused clusters of severe respiratory illness and was associated with 2% mortality. There is currently no vaccine and no specific antiviral treatment recommended for COVID-19. About 20% of the patients were severe and the mainstay of clinical management is largely symptomatic treatment, with organ support in intensive care for seriously ill patients. Therefore, it is urgent to find a safe and effective therapeutic approach to COVID-19.
Tannins have been shown to have antioxidant, anti-inflammatory, antimicrobial properties and a regulatory effect on the gastrointestinal metabolism.
The investigators will realize a prospective, double-blind, randomized trial to assess the effect of treatment with a dietary supplement (ARBOX), a molecular complex of quebracho and chestnut tannins extract and Vit B12, compared with placebo. 140 COVID-19 patients will be recruited in a single center in Buenos Aires Argentina. 70 patients will receive conventional treatment plus ARBOX (treated group) and 70 patients will receive conventional treatment plus placebo (control group). The effects will be evaluated during the 28 days follow up. The primary end point will be the time of discharge from the hospital. A panel of 27 cytokines level, intestinal microbiota composition and its metabolites will be assessed at day 1 and 14.
日期
| 最后验证: | 04/30/2020 |
| 首次提交: | 05/21/2020 |
| 提交的预估入学人数: | 05/25/2020 |
| 首次发布: | 05/26/2020 |
| 上次提交的更新: | 05/25/2020 |
| 最近更新发布: | 05/26/2020 |
| 实际学习开始日期: | 05/31/2020 |
| 预计主要完成日期: | 09/29/2020 |
| 预计完成日期: | 10/30/2020 |
状况或疾病
干预/治疗
Dietary Supplement: TREATED
Other: CONTROL
相
手臂组
| 臂 | 干预/治疗 |
|---|---|
| Experimental: TREATED Participants will receive a supply of 28 -- 390 mg ARBOX capsules for 14 days. Patients will be supplemented with 2 capsules of ARBOX per day and standard therapy.
Standard treatment includes: Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy. | Dietary Supplement: TREATED dry extract of polyphenols (tannins) form quebracho and chestnut 240 mg, B12 vitamin 0.72 µg |
| Placebo Comparator: CONTROL Participants will receive placebo supply for 14 days. The placebo will be administrated with the identical dose as described for the test product.
Beside patients will receive the standard theraphy, which includes Antipyretics or Lopinavir / Ritonavir, Azithromycin and Hydroxychloroquine, as appropriate (treatment currently recommended by the department of Infectious Diseases of the Hospital de Clínicas that could undergo to modifications). In addition, if necessary: supplemental O2, non-invasive ventilation, antibiotic therapy. | Other: CONTROL Matching placebo, twice-daily administration BID as described for the test product, identical number of tablets as given for ARBOX |
资格标准
| 有资格学习的年龄 | 18 Years 至 18 Years |
| 有资格学习的性别 | All |
| 接受健康志愿者 | 是 |
| 标准 | Inclusion Criteria: - Over 18 years of age hospitalized in the general hospitalization room, who meet the definition of "Confirmed case COVID-19" (https://www.argentina.gob.ar/salud/coronavirus-COVID-19/definicion -of-case) Exclusion Criteria: - Pregnancy - Lactancy - Hypersensitivity to polyphenols - Patients unable to receive oral medication (severe cognitive impairment, assisted ventilation, impaired state of consciousness) - Lack of consent - Participation in any other interventional clinical trial |
结果
主要结果指标
1. Time to hospital discharge [Throughout the Study (Day 0 to Day 28)]
次要成果指标
1. 28-day all-cause mortality [Throughout the Study (Day 0 to Day 28)]
2. invasive ventilation on day 28 [Throughout the Study (Day 0 to Day 28)]
3. Difference in Pro and antiinflammatory citoquine levels [day 1-14]
4. Difference in fecal intestinal microbiota composition [day 1-14]
5. Negativization of COVID-PCR at day 14 [day 14]
